# Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients

> **NCT01612078** · PHASE3 · TERMINATED · sponsor: **TSH Biopharm Corporation Limited** · enrollment: 25 (actual)

## Conditions studied

- Orthostatic Hypotension

## Interventions

- **DRUG:** Droxidopa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01612078
- **Lead sponsor:** TSH Biopharm Corporation Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2013-02
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01612078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01612078, "Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01612078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*